For research use only. Not for therapeutic Use.
Avotaciclib hydrochloride(CAT: I041014) is a potent, orally bioavailable selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By targeting CDK4/6, Avotaciclib hydrochloride disrupts cell cycle progression, specifically preventing the transition from the G1 to the S phase, thereby inhibiting tumor cell proliferation. This mechanism of action makes it a promising therapeutic candidate for the treatment of various cancers, including breast cancer, non-small cell lung cancer (NSCLC), and hematologic malignancies. In preclinical and early clinical trials, Avotaciclib hydrochloride has demonstrated significant anti-tumor activity, particularly when combined with other targeted therapies, offering new hope for patients with aggressive cancer types.
Catalog Number | I041014 |
Synonyms | 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol;hydrochloride |
Molecular Formula | C13H12ClN7O |
Purity | ≥95% |
IUPAC Name | 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol;hydrochloride |
InChI | InChI=1S/C13H11N7O.ClH/c14-12-16-5-3-8(19-12)7-1-2-10(21)11(18-7)9-4-6-17-13(15)20-9;/h1-6,21H,(H2,14,16,19)(H2,15,17,20);1H |
InChIKey | ZONRGCMBLZETKM-UHFFFAOYSA-N |
SMILES | C1=CC(=NC(=C1O)C2=NC(=NC=C2)N)C3=NC(=NC=C3)N.Cl |